Shares of Alexion fell more than 11 percent Friday as the office instituted an inter partes review for the drug, Soliris, in the blood disorder paroxysmal nocturnal hemoglobinuria.
On Tuesday, judges heard verbal arguments from both sides of the CRISPR intellectual property fight, a technology that could prove to be the greatest biotech advance in recent history. But the outcome matters less than what is happening in the field right now.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.